Confo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Confo Therapeutics's estimated annual revenue is currently $13.6M per year.
- Confo Therapeutics's estimated revenue per employee is $155,000
- Confo Therapeutics's total funding is $105M.
Employee Data
- Confo Therapeutics has 88 Employees.
- Confo Therapeutics grew their employee count by 5% last year.
Confo Therapeutics's People
| Name | Title | Email/Phone |
|---|
Confo Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.6M | 49 | 29% | N/A | N/A |
#2 | $19.8M | 128 | -14% | N/A | N/A |
#3 | $249.2M | 1608 | 5% | N/A | N/A |
#4 | $28.4M | 183 | -19% | N/A | N/A |
#5 | $7.1M | 46 | 5% | $30.5M | N/A |
#6 | $5M | 32 | -9% | N/A | N/A |
#7 | $16.6M | 107 | 45% | N/A | N/A |
#8 | $6.7M | 43 | 48% | N/A | N/A |
#9 | $24.2M | 156 | -16% | N/A | N/A |
#10 | $13.8M | 89 | 31% | N/A | N/A |
What Is Confo Therapeutics?
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery. The company's strategy is to broadly exploit its technology by building a unique portfolio of therapeutic programs in various disease areas, both for its own pipeline as well as with pharma partners. For more information: www.confotherapeutics.com
keywords:N/A
$105M
Total Funding
88
Number of Employees
$13.6M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Confo Therapeutics News
Confo Therapeutics' unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range...
Confo Therapeutics today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication. The grant w ...
Confo Therapeutics, a Ghent, Belgium-based drug discovery company, completed a €30m ($33.4m) Series A financing. The round was led by BioGeneration Ventures (BGV) and co-led by Wellington Partners, with participation from new investors Fund+ and Perceptive Advisors and existing investors Capric ...
Confo Therapeutics has raised €30 million ($34 million) to take compounds targeting difficult-to-drug GPCRs into clinical development. The series A round (PDF) sets Confo up to advance drugs derived from a novel way of stabilizing GPCRs and performing more sensitive screens. Sponsored by Agilen ...
Other Companies in Zwijnaarde
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.9M | 96 | 22% | N/A |
#2 | $69.8M | 235 | 22% | N/A |
#3 | $139.9M | 244 | 50% | $65M |
#4 | $510.1M | 1338 | 31% | $2B |